cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells
To investigate changes in gene expression associated with ERBB2 , expression profiling of immortalized human mammary luminal epithelial cells and variants expressing a moderate and high level of ERBB2 has been carried out using cDNA microarrays corresponding to approximately 6000 unique genes/ESTs....
Gespeichert in:
Veröffentlicht in: | Oncogene 2003-05, Vol.22 (17), p.2680-2688 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | To investigate changes in gene expression associated with
ERBB2
, expression profiling of immortalized human mammary luminal epithelial cells and variants expressing a moderate and high level of
ERBB2
has been carried out using cDNA microarrays corresponding to approximately 6000 unique genes/ESTs. A total of 61 significantly up- or downregulated (2.0-fold) genes were identified and further validated by RT–PCR analysis as well as microarray comparisons with a spontaneously
ERBB2
- overexpressing breast cancer cell line and
ERBB2
-positive primary breast tumors. The expression and clinical relevance of proteins predicted to be associated with
ERBB2
overexpression in breast cancers were analysed together with their clinical relevance by antibody screening using a tissue array. Differentially regulated genes include those involved in cell–matrix interactions including proline 4-hydroxylase (
P4HA2
), galectin 1 (
LGALS1
) and galectin 3 (
LGALS3
), fibronectin 1 (
FN1
) and p-cadherin (
CDH3
), and cell proliferation (
CRIP1
,
IGFBP3
) and transformation (
S100P
,
S100A4
). A number of genes associated with
MYC
signalling were also differentially expressed, including
NDRG1
,
USF2
and the epithelial membrane proteins 1 and 3 (
EMP1
,
EMP3
). These data represent profiles of the transcriptional changes associated with
ERBB2
-related pathways in the breast, and identify novel and potentially useful targets for prognosis and therapy. |
---|---|
ISSN: | 0950-9232 1476-5594 |
DOI: | 10.1038/sj.onc.1206349 |